Nirsevimab and a Community Recall-Based Immunization Strategy for Child Bronchiolitis Prevention

This cohort study examines the association of a recall-based nirsevimab immunization strategy with the incidence of clinically diagnosed all-cause bronchiolitis during the 2024-2025 respiratory syncytial virus season in Italy.

Corresponding Author: Riccardo Boracchini, PhD, Division of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Via Bicocca degli Arcimboldi 8, 20126 Milan, Italy (riccardo.boracchini@unimib.it).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.